BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 29906532)

  • 21. miR-122 enhances sensitivity of hepatocellular carcinoma to oxaliplatin via inhibiting MDR1 by targeting Wnt/β-catenin pathway.
    Cao F; Yin LX
    Exp Mol Pathol; 2019 Feb; 106():34-43. PubMed ID: 30539797
    [TBL] [Abstract][Full Text] [Related]  

  • 22. miR-577 inhibits glioblastoma tumor growth via the Wnt signaling pathway.
    Zhang W; Shen C; Li C; Yang G; Liu H; Chen X; Zhu D; Zou H; Zhen Y; Zhang D; Zhao S
    Mol Carcinog; 2016 May; 55(5):575-85. PubMed ID: 25764520
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Modulating lncRNA SNHG15/CDK6/miR-627 circuit by palbociclib, overcomes temozolomide resistance and reduces M2-polarization of glioma associated microglia in glioblastoma multiforme.
    Li Z; Zhang J; Zheng H; Li C; Xiong J; Wang W; Bao H; Jin H; Liang P
    J Exp Clin Cancer Res; 2019 Aug; 38(1):380. PubMed ID: 31462285
    [TBL] [Abstract][Full Text] [Related]  

  • 24. miR-124 suppresses glioblastoma growth and potentiates chemosensitivity by inhibiting AURKA.
    Qiao W; Guo B; Zhou H; Xu W; Chen Y; Liang Y; Dong B
    Biochem Biophys Res Commun; 2017 Apr; 486(1):43-48. PubMed ID: 28242198
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Micro-RNA29b enhances the sensitivity of glioblastoma multiforme cells to temozolomide by promoting autophagy.
    Xu JX; Yang Y; Zhang X; Luan XP
    Anat Rec (Hoboken); 2021 Feb; 304(2):342-352. PubMed ID: 32275350
    [TBL] [Abstract][Full Text] [Related]  

  • 26. miR-603 promotes glioma cell growth via Wnt/β-catenin pathway by inhibiting WIF1 and CTNNBIP1.
    Guo M; Zhang X; Wang G; Sun J; Jiang Z; Khadarian K; Yu S; Zhao Y; Xie C; Zhang K; Zhu M; Shen H; Lin Z; Jiang C; Shen J; Zheng Y
    Cancer Lett; 2015 Apr; 360(1):76-86. PubMed ID: 25681036
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of GSH synthesis potentiates temozolomide-induced bystander effect in glioblastoma.
    Kohsaka S; Takahashi K; Wang L; Tanino M; Kimura T; Nishihara H; Tanaka S
    Cancer Lett; 2013 Apr; 331(1):68-75. PubMed ID: 23246370
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Exosomal transfer of miR-1238 contributes to temozolomide-resistance in glioblastoma.
    Yin J; Zeng A; Zhang Z; Shi Z; Yan W; You Y
    EBioMedicine; 2019 Apr; 42():238-251. PubMed ID: 30917935
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Upregulation of miR-1825 inhibits the progression of glioblastoma by suppressing CDK14 though Wnt/β-catenin signaling pathway.
    Lu F; Li C; Sun Y; Jia T; Li N; Li H
    World J Surg Oncol; 2020 Jun; 18(1):147. PubMed ID: 32605563
    [TBL] [Abstract][Full Text] [Related]  

  • 30. p53 upregulated modulator of apoptosis sensitizes drug-resistant U251 glioblastoma stem cells to temozolomide through enhanced apoptosis.
    Miao W; Liu X; Wang H; Fan Y; Lian S; Yang X; Wang X; Guo G; Li Q; Wang S
    Mol Med Rep; 2015 Jun; 11(6):4165-73. PubMed ID: 25625235
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hypoxia-mediated mitochondria apoptosis inhibition induces temozolomide treatment resistance through miR-26a/Bad/Bax axis.
    Ge X; Pan MH; Wang L; Li W; Jiang C; He J; Abouzid K; Liu LZ; Shi Z; Jiang BH
    Cell Death Dis; 2018 Nov; 9(11):1128. PubMed ID: 30425242
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Zinc enhances temozolomide cytotoxicity in glioblastoma multiforme model systems.
    Toren A; Pismenyuk T; Yalon M; Freedman S; Simon AJ; Fisher T; Moshe I; Reichardt JK; Constantini S; Mardor Y; Last D; Guez D; Daniels D; Assoulin M; Mehrian-Shai R
    Oncotarget; 2016 Nov; 7(46):74860-74871. PubMed ID: 27556862
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MicroRNA-106a-5p facilitates human glioblastoma cell proliferation and invasion by targeting adenomatosis polyposis coli protein.
    Li D; Wang Z; Chen Z; Lin L; Wang Y; Sailike D; Luo K; Du G; Xiang X; Jiafu GD
    Biochem Biophys Res Commun; 2016 Dec; 481(3-4):245-250. PubMed ID: 27815074
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Up-regulation of miR-370-3p restores glioblastoma multiforme sensitivity to temozolomide by influencing MGMT expression.
    Gao YT; Chen XB; Liu HL
    Sci Rep; 2016 Sep; 6():32972. PubMed ID: 27595933
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Temozolomide induces activation of Wnt/β-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy.
    Tomar VS; Patil V; Somasundaram K
    Cell Biol Toxicol; 2020 Jun; 36(3):273-278. PubMed ID: 31758290
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Verbascoside inhibits progression of glioblastoma cells by promoting Let-7g-5p and down-regulating HMGA2 via Wnt/beta-catenin signalling blockade.
    Jia WQ; Zhu JW; Yang CY; Ma J; Pu TY; Han GQ; Zou MM; Xu RX
    J Cell Mol Med; 2020 Mar; 24(5):2901-2916. PubMed ID: 32000296
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of STAT3 reverses alkylator resistance through modulation of the AKT and β-catenin signaling pathways.
    Wang Y; Chen L; Bao Z; Li S; You G; Yan W; Shi Z; Liu Y; Yang P; Zhang W; Han L; Kang C; Jiang T
    Oncol Rep; 2011 Nov; 26(5):1173-80. PubMed ID: 21887474
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Blockage of a miR-21/EGFR regulatory feedback loop augments anti-EGFR therapy in glioblastomas.
    Zhang KL; Han L; Chen LY; Shi ZD; Yang M; Ren Y; Chen LC; Zhang JX; Pu PY; Kang CS
    Cancer Lett; 2014 Jan; 342(1):139-49. PubMed ID: 24012640
    [TBL] [Abstract][Full Text] [Related]  

  • 39. RPN2 is targeted by miR-181c and mediates glioma progression and temozolomide sensitivity via the wnt/β-catenin signaling pathway.
    Sun J; Ma Q; Li B; Wang C; Mo L; Zhang X; Tang F; Wang Q; Yan X; Yao X; Wu Q; Shu C; Xiong J; Fan W; Wang J
    Cell Death Dis; 2020 Oct; 11(10):890. PubMed ID: 33087705
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biological basis and clinical study of glycogen synthase kinase- 3β-targeted therapy by drug repositioning for glioblastoma.
    Furuta T; Sabit H; Dong Y; Miyashita K; Kinoshita M; Uchiyama N; Hayashi Y; Hayashi Y; Minamoto T; Nakada M
    Oncotarget; 2017 Apr; 8(14):22811-22824. PubMed ID: 28423558
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.